

Stewart Goldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7245023/publications.pdf>

Version: 2024-02-01

74
papers

3,701
citations

212478

28
h-index

150775

59
g-index

76
all docs

76
docs citations

76
times ranked

5776
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor. <i>Journal of Clinical Oncology</i> , 2009, 27, 385-389.	0.8	397
2	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.	9.4	381
3	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	0.8	368
4	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1011-1022.	5.1	315
5	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
6	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. <i>Neuro-Oncology</i> , 2017, 19, 1135-1144.	0.6	236
7	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
8	Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2464-2471.	0.8	136
9	Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. <i>Neuro-Oncology</i> , 2016, 18, 1319-1325.	0.6	108
10	Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. <i>Neuro-Oncology</i> , 2017, 19, 1279-1280.	0.6	93
11	Self-Reported Worries Among Long-Term Survivors of Childhood Cancer and Their Peers. <i>Journal of Psychosocial Oncology</i> , 1998, 16, 1-23.	0.6	90
12	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2018, 20, 1547-1555.	0.6	82
13	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	0.6	74
14	Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. <i>Neuro-Oncology</i> , 2016, 18, now106.	0.6	73
15	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 6325-6337.	3.9	70
16	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 537-546.	0.6	61
17	Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on Head Start III: a multi-institutional, prospective clinical trial. <i>Neuro-Oncology</i> , 2020, 22, 1862-1872.	0.6	57
18	Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. <i>Clinical Cancer Research</i> , 2019, 25, 5572-5583.	3.2	52

#	ARTICLE	IF	CITATIONS
19	Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 934-943.	0.6	51
20	MR imaging features of diffuse intrinsic pontine glioma and relationship to overall survival: report from the International DIPG Registry. <i>Neuro-Oncology</i> , 2020, 22, 1647-1657.	0.6	51
21	REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1713-1723.	1.9	47
22	Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 165-173.	15.2	46
23	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	0.6	45
24	Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2014, 16, 1554-1559.	0.6	44
25	MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. <i>Molecular Cancer Research</i> , 2016, 14, 984-993.	1.5	38
26	Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. <i>Oncotarget</i> , 2014, 5, 8442-8451.	0.8	35
27	HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. <i>Scientific Reports</i> , 2018, 8, 1211.	1.6	30
28	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. <i>Molecular Cancer Research</i> , 2018, 16, 32-46.	1.5	29
29	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. <i>Journal of Neuro-Oncology</i> , 2018, 136, 475-484.	1.4	22
30	Transcriptional repressor REST drives lineage stage-specific chromatin compaction at <i>Ptch1</i> and increases AKT activation in a mouse model of medulloblastoma. <i>Science Signaling</i> , 2019, 12, .	1.6	19
31	Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. <i>Current Problems in Cancer</i> , 2021, 45, 100777.	1.0	17
32	Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to measure symptom burden reported by patients with brain tumors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27526.	0.8	15
33	Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. <i>Neuro-Oncology</i> , 2020, 22, 1696-1704.	0.6	14
34	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). <i>Neuro-Oncology</i> , 2022, 24, 1178-1190.	0.6	13
35	Computerized Adaptive Testing in Pediatric Brain Tumor Clinics. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 289-297.	0.6	12
36	REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. <i>Oncotarget</i> , 2018, 9, 5233-5250.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 1950-1961.	0.6	12
38	A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. <i>BioTechniques</i> , 2016, 60, 43-6.	0.8	11
39	A cross-sectional study of carnitine deficiency and fatigue in pediatric cancer patients. <i>Child's Nervous System</i> , 2016, 32, 475-483.	0.6	11
40	Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma. <i>Neurosurgery</i> , 2020, 87, E680-E688.	0.6	11
41	A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10065-10065.	0.8	10
42	Parent-reported cognitive function is associated with leukoencephalopathy in children with brain tumors. <i>Quality of Life Research</i> , 2017, 26, 2541-2550.	1.5	9
43	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28833.	0.8	9
44	Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	0.6	9
45	Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. <i>Neuro-Oncology</i> , 2022, 24, 821-833.	0.6	9
46	Getting serious about the early-life epilepsies. <i>Neurology</i> , 2018, 90, 842-848.	1.5	8
47	Pediatric Brain Metastasis from Extraneural Malignancies: A Review. <i>Cancer Treatment and Research</i> , 2007, 136, 143-168.	0.2	8
48	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2035-2035.	0.8	8
49	Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. <i>Journal of Neuro-Oncology</i> , 2009, 95, 289-292.	1.4	7
50	A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27217.	0.8	6
51	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210.	0.6	6
52	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 437-445.	1.4	5
53	Characteristics of children ≥6 months of age with DIPG: A report from the international DIPG registry. <i>Neuro-Oncology</i> , 2022, 24, 2190-2199.	0.6	4
54	LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial. <i>Neuro-Oncology</i> , 2022, 24, i88-i88.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Symptom burden trajectories experienced by patients with brain tumors. <i>Cancer</i> , 2020, 126, 3341-3351.	2.0	2
56	New insights into malignant cell survival mechanisms in medulloblastoma. <i>Cancer Cell & Microenvironment</i> , 2014, 1, .	0.8	2
57	A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2036-2036.	0.8	2
58	OTHR-08. Pediatric Neurologic Assessment in Neuro-oncology (pNANO) Scale: A tool to assess neurologic function for Response Assessment in Neuro-oncology (RAPNO). <i>Neuro-Oncology</i> , 2022, 24, i148-i148.	0.6	2
59	DIPG-33. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. <i>Neuro-Oncology</i> , 2018, 20, i55-i55.	0.6	1
60	QOL-11. SYMPTOM BURDEN EXPERIENCED BY CHILDREN WITH BRAIN TUMORS AND ITS INFLUENTIAL FACTORS. <i>Neuro-Oncology</i> , 2018, 20, i159-i159.	0.6	1
61	Benign skull and subdural lesions in patients with prior medulloblastoma therapy. <i>Child's Nervous System</i> , 2021, 37, 359-366.	0.6	1
62	Retinoblastoma associated with congenital hypotonia: A case report and review of the literature. <i>Journal of Pediatric Neurology</i> , 2015, 04, 265-270.	0.0	0
63	DIPG-36. NOVEL THERAPEUTIC APPROACHES USING NANOLIPOSOMAL SN-38 FOR THE TREATMENT OF HUMAN BRAINSTEM GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, iv13-iv13.	0.6	0
64	SCDT-20. NEW THERAPEUTIC APPROACH FOR BRAINSTEM GLIOMA: INTRANASAL DELIVERY OF NANOLIPOSOMAL SN-38. <i>Neuro-Oncology</i> , 2017, 19, vi269-vi269.	0.6	0
65	RONC-22. IMPACT OF RADIOTHERAPY MODALITY ON NEUROPSYCHOLOGICAL OUTCOMES OF PEDIATRIC BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, i179-i179.	0.6	0
66	PDTM-42. TARGETED INHIBITION OF BET BROMODOMAIN AND JMJD3 PROTEINS FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi212-vi213.	0.6	0
67	Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future. <i>Molecular Biology Reports</i> , 2021, 48, 7537-7544.	1.0	0
68	Parent-reported cognition and its clinical applications in pediatric oncology.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9532-9532.	0.8	0
69	The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pool analysis of cooperative group clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2503-2503.	0.8	0
70	DDEL-11. CONVECTION-ENHANCED DELIVERY OF EZH2 INHIBITOR FOR THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii285-iii286.	0.6	0
71	IMG-04. RESPONSE ASSESSMENT IN PEDIATRIC HIGH-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY WORKING GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii355-iii355.	0.6	0
72	GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials. <i>Neuro-Oncology</i> , 2022, 24, i54-i54.	0.6	0

#	ARTICLE	IF	CITATIONS
73	RARE-13. Clinical management and functional and survival outcomes in pediatric craniopharyngioma, a patient and family perspective. <i>Neuro-Oncology</i> , 2022, 24, i12-i12.	0.6	0
74	RARE-17. Multi-institutional craniopharyngioma cohort highlights need for more comprehensive data collection on comorbidities and quality of life. <i>Neuro-Oncology</i> , 2022, 24, i13-i13.	0.6	0